End Drug Shortages Alliance Association
Nonprofit profile at a glance
- EIN
- 921622956
- IRS 990 coverage
- 2023–2025
- Forms available
- Form 990 2025
- Location
- Wilmington, DE, USA
- Phone
- 3032633452
- Rating confidence
- Limited
- Sector
- Alliance/Advocacy Organizations
Reported finances
- Revenue
- $565,940
- Expenses
- $619,396
- Assets
- $667,810
- Liabilities
- $99,688
Source: IRS Form 990. Selected filing: tax year 2025. Amounts in USD.
Leadership & pay
19 people listed
Executive titles in this filing
- APRIL GILES (EXECUTIVE DIRECTOR)
People named in this filing
- JASON CHOU (CHAIR)
- MIKE WASCOVICH (CHAIR ELECT)
- TERRI LYLE WILSON (PAST CHAIR)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
Lead the nation's only member-driven and industry-led alliance of healthcare and supply chain leaders working collaboratively to strengthen essential medicine supply and safeguard patient access.
What it reported doing in 2025
End drug shortages alliance's (edsa) vision is to end drug shortages through ensuring access to essential medications and improving quality of life for patients who rely on these medications. This year, edsa launched its most ambitious and unifying effort: a coordinated strategy to end drug shortages by scaling successful pilots, driving policy innovation, and aligning national resilience efforts.2025 marked a critical milestone as data collection for the drug resiliency and transparency pilot officially began. This pilot is a first-of-its-kind, collaborative effort guided by a dedicated pilot task force of health system leaders, supply chain experts, and our rapid response team. (continued on schedule o).the pilot is designed to build a scalable, transparent system that ensures consistent access to medications, establishes inventory stewardship best practices, recommends buffer supply strategies, and supports timely drug distribution during shortages. Participating hospitals and distributors submit weekly blinded data and inventory status on seven essential pediatric cancer drugs, which allows us to spot patterns before they become crises, anticipate challenges and improve planning, guide best practices for stewardship and buffer managenent. Edsa added 22 members in 2025, growing to 100 active members across the drug supply chain. With this growth comes greater strength, greater reach, and a greater ability to deliver results that matter.
Operating model
- Revenue model
- Earned-program. 100% of the money available for current operations came from fees and other program revenue.
- Distribution model
- Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.
The verdict
- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.
Rating breakdown
- Financial Efficiency: NotEnoughData
- Transparency & Controls: 90
- Accountability: 88
- Sustainability: 32
- Growth: 60
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: Limited
- Program expense ratio: Limited
- Fundraising efficiency: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
- Pay-setting controls: Limited
- Foreign activity oversight: Limited
- Grant itemization coverage: Limited
- Major donor itemization: Limited
- Related-party transparency: Limited
Accountability
- Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
- Governance controls: 5 of 7 controls in place; rating input score 71
- Conflict-of-interest policy: Pass
- Whistleblower policy: Pass
- Document-retention policy: Pass
- CEO compensation review process: NotApplicable
- Other executive compensation review process: NotApplicable
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Missing
- Independent financial-statement audit: Fail
Sustainability
- Operating margin: -9.4%; rating input score 14; 14th percentile among comparable filings
- Total-asset coverage ratio: 1.08; rating input score 45; 45th percentile among comparable filings
- Liabilities to assets ratio: 0.15; rating input score 29; 29th percentile among comparable filings
- Officer compensation ratio: 0%; rating input score 78; 78th percentile among comparable filings
Growth
- Program expense growth: Limited
- Revenue growth: 22.9% per year; rating input score 100; 86th percentile among comparable filings
- Asset growth: 25.8% per year; rating input score 100; 86th percentile among comparable filings
Details
- Where the money goes: Financial trends and filed revenue, expense, asset, and liability detail
- Governance: 18 of 18 board members independent · 5 of 7 filing controls reported
- Programs: 1 filed program accomplishment
- Leadership: top reported pay $0 · 19 people listed
- Consistency: 9 of 9 current checks pass
- Schedules: 1 filed schedules
- Filing history: 3 filing years from 2023 to 2025
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Sustainability: Operating margin scored 14/100.
- Review — Accountability: Governance controls: Independent financial-statement audit not reported.
- Moderate — Sustainability: Total-asset coverage ratio scored 45/100.
- High — Sustainability: Liabilities to assets ratio scored 29/100.